Antiphospholipid syndrome (APS) is characterized by thrombosis and/or recurrent pregnancy loss in the presence of antiphospholipid antibodies (APLA). The majority of APLA are directed against phospholipid binding proteins, particularly β 2 GPI. Anti-β 2 GPI antibodies activate endothelial cells in a β 2 GPI-dependent manner through a pathway that involves NF-κB. Krüppellike factors (KLFs) play a critical role in regulating the endothelial response to inflammatory stimuli. We hypothesized that activation of endothelial cells by APLA/anti-β 2 GPI antibodies might be associated with decreased expression of KLFs, which in turn might facilitate cellular activation mediated through NF-κB. Our experimental results confirmed this hypothesis, demonstrating markedly decreased expression of KLF2 and KLF4 following incubation of cells with APLA/anti-β 2 GPI antibodies. Restoration of KLF2 or KLF4 levels inhibited NF-κB transcriptional activity and blocked APLA/anti-β 2 GPI-mediated endothelial activation despite NF-κB p65 phosphorylation. chIP analysis demonstrated that inhibition of NF-κB transcriptional activity by KLFs reflects sequestration of the co-transcriptional activator CBP/p300, making this cofactor unavailable to NF-κB. These findings suggest that the endothelial response to APLA/anti-β 2 GPI antibodies reflects competition between KLFs and NF-κB for their common cofactor, CBP/p300. Taken together, these observations are the first to implicate the KLFs as novel participants in the endothelial proinflammatory response to APLA/anti-β 2 GPI antibodies.
INTRODUCTION
The Antiphospholipid Syndrome (APS) is characterized by arterial or venous thrombosis and/or recurrent fetal loss in the presence of antiphospholipid antibodies (APLA) 1-3 . It is now widely accepted that the majority of pathologic antibodies in patients with this disorder are actually directed against phospholipid-binding proteins, the most common of which is β 2 -glycoprotein I (β 2 GPI).
The pathogenesis of APS-associated thrombosis is multifactorial, and a number of mechanisms have been proposed 4 . These include inhibition of protein C activation and activity 5;6 , inhibition of annexin V assembly on exposed phospholipid surfaces 7 , and prevention of appropriate interactions of antithrombin with glycosaminoglycans 8 , among others 4;9 . Studies from our laboratory and others suggest that β 2 GPI-dependent activation of vascular cells by APLA/antiβ 2 GPI antibodies plays a central role in disease pathogenesis 10;11 , and may initiate the cascade of events that leads to thrombus development. For example, β 2 GPI binds to endothelial cell annexin A2, and subsequent cross-linking of annexin A2-bound β 2 GPI initiates endothelial cell activation through a pathway that may involve toll-like receptor 4 (TLR-4) [11] [12] [13] and leads to activation of NF-κB 14 . A similar pathway may be functional in monocytes, activation of which also contributes to the development of thrombosis in patients with APLA 15 . Additionally, APLA may promote platelet activation in the presence of sub-threshold concentrations of agonists 16 , though whether this is a receptor-mediated process, and if so, its relationship to platelet β 2 GPI binding sites such as GP1b 17 and apoER2 18 requires further study.
In endothelial cells, activation of NF-κB stimulates an inflammatory and procoagulant response 19 and plays a critical role in the ability of APLA to promote thrombosis 20 . Thus, modulation of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From NF-κB activity may provide an opportunity to reverse the pathologic vascular response in APS.
The Krüppel-like factors (KLFs) 21 , particularly KLF2 and KLF4, inhibit inflammatory cytokinemediated responses in endothelial cells 22;23 , at least in part through inhibition of NF-κB activity 23 . However, expression of KLF2 itself may be inhibited by inflammatory cytokines and/or vascular injury [23] [24] [25] , though the expression of KLF4 appears to be increased under these conditions 26 .
In considering the importance of NF-κB in endothelial cell activation mediated by APLA/antiβ 2 GPI antibodies 14 and the potentially opposing effects of KLF2 and KLF4, we hypothesized that changes in expression of these transcription factors might influence the endothelial cell response to APLA/anti-β 2 GPI antibodies. Here, we report that unlike responses to inflammatory cytokines, the expression of both KLF2 and KLF4 is decreased in response to APLA/anti-β 2 GPI antibodies. Moreover, restoring the expression of these KLFs blocks endothelial cell activation in response to APLA/anti-β 2 GPI antibodies. These activities result from inhibition of NF-κB transcriptional activity through sequestration of the transcriptional coactivator, CBP/p300, by KLFs.
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Materials and Methods

Materials
All reagents were purchased from Sigma (St Louis, MO) unless otherwise specified. Expression plasmids containing KLF2 and KLF4 open reading frames (ORF) have been previously described 23; 27 . An expression plasmid containing the CBP/p300 ORF was a kind gift from Dr.
Andreas Hecht (Institut für Molekulare Medizin und Zellforschung, Freiburg, Germany). An NF-κB luciferase reporter construct was obtained from Stratagene (Santa Clara, CA), and an Eselectin luciferase reporter was a kind gift from Dr. Paul DiCorleto, Cleveland Clinic Foundation, Cleveland, OH. A dominant negative NF-κB plasmid construct (IkB superrepressor mutant) was a kind gift from Dr. Nywana Sizemore (Cleveland Clinic Foundation). Goat antihuman E-selectin antibodies (C20) and antibodies against the NF-κB p65 subunit were from Santa Cruz Biologicals (Santa Cruz, CA). Antibodies against NF-κB phospho-p65 ser 536 were from Cell Signaling Technologies (Beverly, MA). Antibodies against human KLF4 were from CeMines (Golden, CO). Antibodies against β -actin were from Abcam (Cambridge, MA).
Control rabbit immunoglobulin G (IgG) and murine IgG1 (MOPC-21) were from Zymed Laboratories (South San Francisco, CA Anti-β 2 GPI antibodies from rabbits immunized with β 2 GPI were affinity purified using a column of Affigel HZ to which purified human β 2 GPI was coupled (Bio-Rad Laboratories, Hercules, CA) 11 . Antibodies from an APS patient with high titers of anti-β 2 GPI antibodies (> 70 GPL units) and recurrent deep venous thrombosis were affinity-purified in an identical manner.
Cell Culture and reagents
Human umbilical vein endothelial cells (HUVEC) were isolated as previously described 28 . Cells were maintained in Medium 199 containing 10% fetal bovine serum, penicillin-streptomycin, and endothelial cell growth supplement, isolated as described by Maciag et al 29 . Cells were maintained at 37° Celsius in a humidified atmosphere of 10 percent CO 2 and 90 percent air. All experiments were performed using HUVEC of passage 3 or lower.
Purification of β 2 GPI β 2 GPI was isolated as described previously 12 . Briefly, outdated, fresh frozen plasma was subjected to precipitation with polyethylene glycol. The precipitate was collected by centrifugation, and β 2 GPI was subsequently isolated by sequential chromatography on heparinultraflow (Sterogene, Seattle, WA) and S-sepharose (Amersham-Pharmacia, Piscataway, NJ). In a final step, the isolated protein was run through a Detoxigel column to remove contaminating endotoxin. Purified β 2 GPI migrated as a single band of ~50 kDa under non-reducing conditions, with an apparent increase to ~62 kDa after reduction, and was recognized on immunoblotting by anti-β 2 GPI antibodies.
Immunoblotting
For immunoblotting studies, endothelial cells grown to confluency on 6 cm 2 plates were treated with test reagents and washed with ice cold PBS prior to preparation of cell extracts in RIPA buffer (Tris 50mM, 150 mM NaCl, 0.1% SDS, 0.5% Sodium deoxycholate, 1% NP-40)
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From containing 1 mM PMSF and a 1:100 dilution of protease inhibitor cocktail. Alternatively, protein was precipitated from cell extracts prepared using Trizol (for RNA isolation). Briefly, following isolation of RNA and ethanol precipitation of DNA, proteins were precipitated from the remaining phenol-containing supernatant with acetone, and the precipitate resuspended in RIPA buffer. Protein concentrations were determined using the BIO-RAD protein assay, with BSA as standard. Equal amounts of protein (10-100 μg) from cells treated under different experimental conditions were separated on a 12 percent SDS-PAGE gel, and then transferred to a PVDF membrane. Membranes were blocked overnight using 3% BSA in PBS, and then blotted with primary antibodies against NF-κB p65, phospho-p65 ser 536, beta actin or KLF4. Bound primary antibody was detected using species-specific horseradish peroxidase-conjugated secondary antibodies at a concentration of 1:2,000-1:5,000. Bands were visualized using ECL-Plus reagent and exposure to autoradiography film.
Assessment of endothelial cell activation
Endothelial cell activation in response to APLA/anti-β 2 GPI antibodies was assessed primarily by the use of a previously-described ELISA for measurement of E-selectin expression on the endothelial cell surface 11 . Briefly, confluent monolayers of endothelial cells in 96 well microplates were incubated with test materials for 4 hours, then washed and fixed using 0.1% glutaraldehyde. Cells were then blocked with PBS containing 5% non-fat milk, washed with Tris-buffered saline containing 0.01% Tween 20 (TBS-T), and incubated with 1 μg/ml goat antihuman E-selectin. Bound antibodies were detected using a 1:6000 dilution of horseradish peroxidase-conjugated rabbit anti-goat IgG, followed by the peroxidase substrate, Turbo-TMB.
Relative amounts of endothelial cell bound E-selectin antibodies were determined by measuring A 450 .
In selected experiments, we also measured the effect of β 2 GPI/anti-β 2 GPI antibodies on Eselectin transcriptional activity. Briefly, endothelial cells were co-transfected with 0.5 µg of plasmid containing the E-selectin promoter coupled to luciferase, and an identical amount of Renilla-luciferase plasmid (as a control for transfection efficiency). Forty-two hours following transfection, cells were incubated for 5 hours with medium alone, β 2 GPI (100 nM) and rabbit anti-human β 2 GPI antibodies (600 nM), or TNFα (10 ng/mL 
Measurement of KLF2, KLF4 and E-selectin expression by quantitative real time PCR (qPCR)
Quantitative real time PCR (qPCR) was used to assess levels of KLF2 and/or KLF4 following incubation of endothelial cells with β 2 GPI and/or anti-β 2 GPI antibodies, using a previouslydescribed protocol 26 . Briefly, total RNA was isolated using Trizol. One microgram of total RNA was treated with DNAse I (Invitrogen) for 15 minutes at room temperature, after which the reaction was stopped via addition of 2.5 mM EDTA and heating at 65 degrees for 10 minutes. Table 1 ). The following parameters were used for qPCR: denaturation at 94° C for 10 min followed by 40 cycles of 95° C for 15 seconds and 62° C for 60 seconds.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Fold induction was calculated after normalization to GAPDH using the Δ Δ Ct method 30 . Dissociation curves showed a single amplification product in each reaction. All data represents at least 4 experiments, with each data point performed in triplicate.
Effects of KLF2, KLF4 and CBP/p300 on cellular activation
To assess the effects of KLF2, KLF4 and CBP/p300 on the response of endothelial cells to APLA/anti-β 2 GPI antibodies, we modulated the cellular levels of these factors by transfecting endothelial cells with expression vectors for the KLFs. Briefly, cells were plated in 12 well plates and allowed to achieve confluence. KLF2 or KLF4 expression was induced through transient transfection using Lipofectamine 2000. Briefly, each well was incubated with plasmid DNA for 3 hours (in experiments where transfection with more than one plasmid was performed simultaneously, scrambled DNA was used to assure that each well received the same amount of total DNA), after which the DNA/transfection reagent mixture was replaced with fresh serumfree medium. Cells were then incubated for 24 hours, washed with PBS, replated in 96-well plates, and incubated overnight at 37 C. Eighteen hours after replating (42 hours post-For personal use only. on September 24, 2017. by guest www.bloodjournal.org From transfection), cells were incubated for 5 hours with either medium alone, β 2 GPI (100 nM) and rabbit anti-human β 2 GPI antibodies (600 nM), or TNFα (10 ng/mL). Cells were then analyzed for cell surface E-selectin expression.
In selected experiments, we used a CBP/p300 expression plasmid or siRNA to CBP/p300 to determine whether manipulation of intracellular levels of CBP/p300 modulated the cellular response to APLA/anti-β 2 GPI antibodies in the absence or presence of plasmid-mediated expression of KLF2 or KLF4. Briefly, endothelial cells were transfected simultaneously with non-targeting siRNA (scrRNA, control) or specific siRNA to CBP/p300, or a CBP/p300 expression plasmid in the absence or presence of expression plasmids for KLFs, and an NF-κBluciferase reporter plasmid. For these studies, plasmid and siRNA was introduced into cells via electroporation using the HUVEC Nucleofector kit and Nucleofector transfection device (Lonza, Walkersville MD), and cultured for 36 hours prior to exposure to test reagents and measurement of luciferase activity.
Assessment of NF-κB phosphorylation, nuclear translocation and transcriptional activity
Phosphorylation, nuclear translocation, and transcriptional activity of NF-κB were assessed using complementary approaches. NF-κB phosphorylation and nuclear translocation was assessed in cytoplasmic and nuclear extracts by immunoblotting with antibodies specific for p65 Ser536.
Nuclear or cytoplasmic extracts were prepared as previously described 31 . Briefly, extracts were first prepared in a buffer containing 10 mM Tris-HCl, pH 8.0, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, protease inhibitors, and 0.1% NP-40, then centrifuged at 2,500 rpm at 4ºC for 5 minutes and the supernatant saved as the cytoplasmic extract. The nuclear pellet was resuspended in a buffer containing 20 mM Tris-HCl (pH 8.0), 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, and 25% glycerol, and 5M NaCl was then added to reach a final NaCl concentration of 400 mM. Samples were incubated for 10 minutes on ice, then vortexed and centrifuged at 14,500 rpm for 4 minutes; the supernatant was saved as the nuclear extract.
To assess NF-κB transcriptional activity, endothelial cells were co-transfected with 0.5 µg of a plasmid containing the NFκB promoter coupled to luciferase, and an identical amount of Renillaluciferase plasmid. After exposure of cells to APLA/anti-β 2 GPI antibodies, NF-κB transcriptional activity was measured and normalized to Renilla luciferase as described for Eselectin.
ChIP-qPCR Assay
ChIP-qPCR assays were performed as previously described 32 . Endothelial cells were transfected with scrDNA or KLF expression vectors. Twenty four hours later, media was removed and cells incubated for an additional 5 hours in medium containing either no additives (control) or β 2 GPI and anti-β 2 GPI antibodies. Cells were then treated with 1% formaldehyde for 15 minutes, and cell lysates were prepared and sheared by sonication. Lysates were pre-cleared by incubation for 3 hours with protein G-Sepharose beads, using salmon sperm DNA and BSA as blocking agents.
Equal amounts of chromatin were then immunoprecipitated using either an antibody to CBP/p300 (Abcam) or control rabbit IgG. After dissociation of protein from DNA, and purification of DNA using phenol-chloroform extraction, the purified DNA was used as a template for qPCR amplification using primers that amplified all three NF-kB binding sites on the E-selectin promoter ( Table 1) . As an internal control, primers for GAPDH were used to amplify corresponding sequences from the same templates. Reactions were performed in triplicate and data are presented as fold change over DNA input.
Statistical Analysis
Data points are expressed as the mean plus or minus standard error (SEM). All experimental points were measured in triplicate or quadruplicate, and all assays were repeated a minimum of 3 times. Differences between control and experimental conditions were assessed using the Student's two-tailed t test for paired samples. Statistical significance was defined as P <0.05.
Results β 2 GPI and anti-β 2 GPI antibodies activate endothelial cells
Previous studies from our laboratory and others have shown that anti-β 2 GPI antibodies activate endothelial cells in the presence of β 2 GPI 10;11 . We confirmed that incubation of endothelial cells with β 2 GPI and anti−β 2 GPI antibodies induced endothelial cell activation, as determined by measurement of cell surface E-selectin expression. Both β 2 GPI and anti-β 2 GPI antibodies were required for activation, since cells incubated with β 2 GPI or anti-β 2 GPI antibodies alone were not activated (Supplemental Figure 1A ). Similar results were seen when affinity-purified human anti-β 2 GPI antibodies from a patient with APS were incubated with endothelial cells in the presence of β 2 GPI (Supplemental Figure 1B ). Endothelial cell activation in both experiments was similar in magnitude to that which occurred in response to10 ng/mL TNFα. The fact that endothelial cell activation occurred over a wide range of β 2 GPI and anti-β 2 GPI concentrations,
with increased E-selectin expression at higher anti-β 2 GPI antibody concentrations (Supplemental Figure 2 ) is consistent with activation occurring through a specific, receptor-mediated process.
Endothelial cell activation induced by APLA/anti-β 2 GPI antibodies results in decreased expression of KLF2 and KLF4
In order to examine the effects of APLA/anti-β 2 GPI antibody-induced endothelial cell activation on the expression of KLF2 and KLF4, we used quantitative PCR to measure the expression of mRNA encoding these transcription factors in endothelial cells exposed to β 2 GPI and anti-β 2 GPI antibodies. We observed a profound decrease in the expression of both KLF2 and KLF4 mRNA in endothelial cells treated in this manner ( Figure 1A) , which was maximal between 6 and 12 hours (Supplemental Figure 3 ) after addition of β 2 GPI and anti-β 2 GPI antibodies to cells. These changes contrasted with those that occurred in response to TNFα, which caused decreased KLF2 expression accompanied by increased expression of KLF4 ( Figure 1A ). Decreased expression of KLF4 by endothelial cells exposed to β 2 GPI and anti-β 2 GPI antibodies corresponded to decreased KLF4 protein ( Figure 1B ) though a lack of suitable antibodies to KLF2 precluded us from parallel analyses of KLF2 protein.
Restoration of KLF2 or KLF4 expression blocks APLA-mediated activation
KLF2 and KLF4 preserve endothelial cell homeostasis by maintaining cells in a non-activated state; thus, the decreased expression of these factors that occurs in response to APLA/anti-β 2 GPI antibodies would be expected to be permissive for cellular activation. To address this hypothesis, we determined whether restoration of KLF2 and KLF4 levels through plasmid-mediated expression blocked endothelial cell activation in response to APLA/anti-β 2 GPI antibodies.
Endothelial cells were transfected with KLF2 and KLF4 expression plasmids, and subsequently incubated in the presence of β 2 GPI and anti-β 2 GPI antibodies. Expression of either transcription factor blocked endothelial cell activation, as determined by a failure of transfected cells to augment cell surface E-selectin expression ( Figure 2A ). Inhibition of E-selectin expression occurred at the transcriptional level, since unlike cells transfected with a control vector, KLF2 or KLF4-transfected cells neither increased transcription of an E-selectin promoter-luciferase reporter construct ( Figure 2B ), nor did they increase production of E-selectin mRNA, as determined using quantitative PCR ( Figure 2C ). These results demonstrate that KLF2 and/or KLF4 maintain endothelial cells in a quiescent state in the presence of APLA/anti-β 2 GPI antibodies, and suggest that decreased expression of these factors in response to such antibodies plays a permissive role in the endothelial cell activation response.
Expression of KLF2 or KLF4 inhibits NF-κB transcriptional activity in response to APLA/anti-
Previous studies have demonstrated that APLA/anti-β 2 GPI antibody-mediated cellular activation occurs, at least in part, through stimulation of NF-κB, leading to downstream responses that enhance cellular procoagulant and inflammatory activity 19 . We confirmed that in the system used in these studies, inhibition of NF-κB using a dominant negative NF-κB construct blocked endothelial cell activation as determined by transcription of E-selectin mRNA (Supplemental Figure 3C ). In fact, the increase in phospho-p65 in nuclear extracts induced by APLA treatment was similar to that observed for TNFα.
Inhibition of NF-κB activity in APLA/β 2 GPI-treated HUVEC by KLF2 involves CBP/p300
Previous studies have demonstrated that the transcriptional coactivator CBP/p300 may interact with and serve as a cofactor for both KLFs and NF-κB 24; [33] [34] [35] . This consideration, taken together with the results depicted in Figure 3 , suggested that the ability of KLF2 and KLF4 to inhibit APLA/anti-β 2 GPI antibody-stimulated NF-κB transcriptional activity without impairing NF-κB p65 phosphorylation or nuclear translocation might reflect an indirect effect of the KLFs on NFκ B. To address this issue, we transfected endothelial cells with KLF2 or KLF4 in the absence or presence of a CBP/p300 expression vector; all cells were also co-transfected with an NF-κB
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From luciferase reporter vector. Cells were then incubated with APLA/anti-β 2 GPI antibodies, and cellular activation assessed in parallel with NF-κB transcriptional activity. These studies demonstrated that expression of CBP/p300 partially restored NF-κB transcriptional activity in APLA/anti-β 2 GPI treated endothelial cells that had been transfected with a KLF2 expression vector ( Figure 4A) . Similar results were observed in KLF4-transfected cells, though their magnitude was of borderline statistical significance (P=0.056), suggesting that additional mechanisms may underlie the ability of KLF4 to inhibit endothelial activation by APLA/antiβ 2 GPI antibodies ( Figure 4B ).
In order to examine the dependence of these effects on CBP/p300, we also determined the effects of siRNA-mediated knockdown of CBP/p300 on NF-κB activity in endothelial cells exposed to APLA/anti-β 2 GPI antibodies following transfection with KLF2 or KLF4 expression vectors. In these studies, cells were simultaneously transfected with siRNA to CBP/p300, and either KLF2, KLF4, or scrambled DNA, and an NF-κB luciferase reporter. Cells were then incubated with β 2 GPI and anti-β 2 GPI antibodies, and luciferase activity measured in cell lysates. We observed that siCBP/p300 diminished NF-κB activity in endothelial cells exposed to APLA/anti-β 2 GPI antibodies regardless of the whether cells had been co-transfected with KLF2 or KLF4 expression vectors ( Figure 5 ). These results suggest that CBP/p300 plays an essential role in regulating the activation state of endothelial cells in response to APLA/anti-β 2 GPI antibodies, presumably by serving as a co-activator with NF-κB, and supports a model in which KLFs regulate the activity of NF-κB by competing with NF-κB for CBP/p300 cofactor activity. The fact that CBP/p300 knockdown did not block endothelial cell activation induced by TNFα suggests a different activation mechanism by the latter.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From To further explore this proposed model, we performed a chromatin immunoprecipitation (chIP) assay to determine whether plasmid-mediated expression of KLF2 or KLF4 in endothelial cells blocked the ability of CBP/p300 antibodies to immunoprecipitate DNA sequences encompassing NF-κB binding sites in the E-selectin promoter after exposure of cells to β 2 GPI and anti-β 2 GPI antibodies. Briefly, cells were transfected with scrambled DNA or KLF2 or KLF4 expression vectors, then exposed to β 2 GPI and anti-β 2 GPI antibodies. Following this incubation and the induction of protein-DNA cross-links, lysates were immunoprecipitated with anti-CBP/p300
antibodies and DNA isolated and amplified using primers specific for the NF-κB binding sites in the E-selectin promoter. In cells transfected with scrambled DNA, immunoprecipitation with the CBP/p300 antibody co-precipitated DNA that was potently amplified by these primers. In contrast, amplification of DNA from CBP/p300 immunoprecipitates of KLF2 or KLF4transfected cells yielded a signal that was only slightly increased above the baseline obtained from control cells ( Figure 6 ). These studies are consistent with our hypothesis that KLF2 or KLF4 sequesters CBP/p300, blocking its interactions with NF-κB and thus its coactivator activity for NF-κB transcriptional targets.
DISCUSSION
The association of APLA/anti-β 2 GPI antibodies with thrombosis is widely appreciated, and recent studies have directly demonstrated that affinity-purified anti-β 2 GPI antibodies induce thrombosis in an animal model 36 . However, the mechanisms underlying APLA/anti-β 2 GPImediated thrombosis remain incompletely understood. These antibodies inhibit key components of several naturally-occurring anticoagulant pathways, including the thrombomodulin-mediated activation of protein C 37 , the activity of activated protein C 28 , and the assembly of the annexin V crystal shield on exposed phospholipid surfaces, among others 7 . However, in order for such anticoagulant activities to be relevant, it is likely that a triggering event leading to activation of coagulation with attendant thrombin generation may be necessary. We hypothesize that this initial event involves, at least in part, the activation of endothelial cells, leading to increased expression of cell surface adhesion molecules that promote monocyte and platelet adhesion, 11;38 the elaboration of microparticles [38] [39] [40] and the expression of tissue factor 41;42 . Support for this hypothesis is supported by studies demonstrating that anti-β 2 GPI antibodies activate endothelial cells in a β 2 GPI-dependent manner 11 , and that elevated levels of endothelial cell and plateletderived microparticles circulate in patients with APLA/anti-β 2 GPI antibodies, even in the absence of an acute thrombotic event 11;38;40;43 . Defining the molecular pathways that facilitate vascular cell activation in patients with these antibodies may provide additional insight into disease pathogenesis, and potentially suggest new directions for more specific therapeutic intervention than indefinite anticoagulation.
In this manuscript we demonstrate that APLA/anti-β 2 GPI antibodies perturb a critical regulatory pathway that plays a central role in maintaining vascular homeostasis. Incubation of endothelial cells with APLA/anti-β 2 GPI antibodies led to profoundly decreased expression of Krüppel like
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From factors 2 and 4, the primary KLFs present in endothelium 22 . Interestingly, this response appears to be unique to APLA/anti-β 2 GPI antibodies, as inflammatory cytokines such as IL-1 and TNFα decrease the expression of KLF2, but increase the expression of KLF4 25 26 . Additional studies will be required to define the regulatory elements that underlie these diverse responses.
Nevertheless, the dual decrease in expression of these factors in response to APLA/anti-β 2 GPI antibodies is likely to be a potent facilitator of endothelial cell activation.
We have also confirmed previous reports suggesting a key role for NF-κB in the response of endothelial cells to APLA/anti-β 2 GPI induced activation 19 , and demonstrated that restoration of KLF2 and/or KLF4 levels blocked endothelial cell activation in response to these antibodies through an indirect effect on NF-κB transcriptional activity. In the presence of KLF2 or KLF4, NF-κB was activated normally, as determined by phosphorylation of serine 536 of the p65 subunit and translocation of p65 to the nucleus; however the transcriptional activity of NF-κB was inhibited, as measured using an NF-κB promoter construct. Subsequent experiments demonstrated that this decrease in transcriptional activity by Krüppel-like factors was due to sequestration of CBP/p300, an essential transcriptional coactivator for NF-κB 24;35 . Support for this mechanism is provided by the observation that decreasing the expression of CBP/p300 using specific siRNA completely blocked endothelial cell activation in response to APLA/anti-β 2 GPI antibodies, presumably by reducing the availability of CBP/p300 for binding NF-κB and enhancing its transcriptional activity. Finally, using chIP, we demonstrated that immunoprecipitation of CBP/p300 protein led to co-precipitation of NF-κB binding sites within the E-selectin promoter. However, plasmid-mediated expression of KLF2 or KLF4 prevented the co-immunoprecipitation of these sequences ( Figure 6 ). Thus, we propose that a dynamic equilibrium exists between the KLFs, NF-κB and CBP/p300, and that the state of this For personal use only. on September 24, 2017. by guest www.bloodjournal.org From equilibrium regulates the susceptibility of endothelial cells to APLA/anti-β 2 GPI-induced activation. Indeed, we hypothesize that the decreased expression of KLFs that occurs in response to APLA/anti-β 2 GPI antibodies is essential for cellular activation, by freeing additional CBP/p300 for interactions with NF-κB. These findings also suggest that modulation of CBP/p300 activity might represent a potential pathway for desensitizing vascular endothelium to the effects of APLA/anti-β 2 GPI antibodies, since reduction of CBP/p300 levels using specific siRNA blocked the ability of these antibodies to activate endothelial cells even when KLF levels were maintained through the use of expression vectors.
In endothelial cells, KLF2 stimulates the expression of numerous genes associated with endothelial quiescence and the maintenance of anti-thrombotic properties 23;24;44 . Induction of thrombomodulin and eNOS, with decreased expression of PAI-1 provide just a few examples of the more than 1000 genes whose expression is altered following KLF2 overexpression 23 .
Several studies have also demonstrated that statins, primarily fluvastatin, inhibit the expression of adhesion molecules 45 and tissue factor 23;46 on endothelial cells exposed to APLA, and in one report treatment of mice with fluvastatin inhibited the thrombogenic properties of APLA in the cremasteric muscle vasculature and femoral vein following mechanical injury 23;47 . However, the molecular mechanisms underlying these effects were not defined. Recent work has demonstrated that several of the statins, including mevastatin, simvastatin and lovastatin, are potent inducers of KLF2 in endothelial cells, and that the ability of statins to stimulate thrombomodulin and eNOS expression is KLF2-dependent 48;49 . The expression of KLF4 is also increased in the presence of simvastatin, lovastatin, and mevastatin 50;51 , and this increase is dependent upon ERK activation, and confers vasoprotection 50 . Taken together, these observations suggest that a potential mechanism by which statins may inhibit the thrombogenic properties of APLA/anti-β 2 GPI For personal use only. on September 24, 2017. by guest www.bloodjournal.org From antibodies may involve inhibition of the ability of these antibodies to decrease the expression of KLFs, a situation that we hypothesize is essential for NF-κB transcriptional activity. Additional studies using in-vitro and in-vivo models will be needed to examine this hypothesis further.
In summary, our studies support a model in which APLA/anti-β 2 GPI-mediated inhibition of KLF expression facilitates activation of endothelial cells by promoting the deregulated activation and transcriptional activity of NF-κB and the expression of downstream prothrombotic, proinflammatory genes. These findings provide new insight into the molecular mechanisms of APLA/anti-β 2 GPI mediated endothelial cell activation that may have therapeutic implications.
Additional studies using in vivo approaches should aid in further defining these mechanisms. and then incubated with medium alone or with β 2 GPI and anti-β 2 GPI antibodies for 5 hours.
Following formaldehyde treatment, cell lysates were immunoprecipitated with control IgG or anti-CBP/p300 antibodies and DNA within the immunoprecipitates was isolated and amplified
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